Wilms tumours (WTs) have two distinct types of histology with or without ectopic mesenchymal elements, suggesting that WTs arise from either the mesenchymal or epithelial nephrogenic lineages. Regardless of the presence or absence of CTNNB1 mutations, nuclear accumulation of b-catenin is often observed in WTs with ectopic mesenchymal elements. Here, we addressed the relationship between the WNT-signalling pathway and lineage in WTs by examining CTNNB1 and WT1 mutations, nuclear accumulation of b-catenin, tumour histology and gene expression profiles. In addition, we screened for mutations in WTX, which has been proposed to be a negative regulator of the canonical WNT-signalling pathway. Unsupervised clustering analysis identified two classes of tumours: mesenchymal lineage WNT-dependent tumours, and epithelial lineage WNT-independent tumours. In contrast to the mesenchymal lineage specificity of CTNNB1 mutations, WTX mutations were surprisingly observed in both lineages. WTX-mutant WTs with ectopic mesenchymal elements had nuclear accumulation of b-catenin, upregulation of WNT target genes and an association with CTNNB1 mutations in exon 7 or 8. However, epithelial lineage WTs with WTX mutations had no indications of active WNT signalling, suggesting that the involvement of WTX in the WNT-signalling pathway may be lineage dependent, and that WTX may have an alternative function to its role in the canonical WNT-signalling pathway.
Introduction
WNT signalling plays a role in embryogenesis and carcinogenesis (Clevers, 2006) . The most well-characterized WNT pathway is the canonical b-catenin/Tcfmediated pathway, which stabilizes b-catenin and leads to translocation of the protein to the nucleus (Clevers, 2006) . Nuclear accumulation of b-catenin is therefore a surrogate marker for activation of the WNT-signalling pathway in many types of cancers (Clevers, 2006) .
Wilms tumour (WT) is an embryonal tumour that recapitulates kidney development. WT typically has a triphasic histology, which consists of varying proportions of blastemal, epithelial and stromal elements (Beckwith et al., 1990) . The stromal tissues occasionally contain ectopic mesenchymal elements such as rhabdomyoblasts, chondrocytes and adipocytes. Remarkably, the presence or absence of ectopic mesenchymal elements in WT histology is associated with specific precursor lesions, intralobar and perilobar nephrogenic rests (ILNR and PLNR), respectively (Beckwith et al., 1990) . The different localization of the nephrogenic rests (ILNR in the centre and PLNR in the periphery of the renal lobe) indicates that ILNR and PLNR occur in the early and late kidney development, respectively (Beckwith et al., 1990) . As ILNR-derived tumours have ectopic mesenchymal elements and PLNR-derived tumours do not, the distinction of the associated WT histology suggests that ILNR have the potential for mesenchymal differentiation including renal epithelial development, whereas PLNR have a limited potential toward nephrogenic epithelial differentiation. Therefore, the timing of kidney developmental errors determines distinct types of nephrogenic rests containing progenitor cells that are committed to different lineages (Fukuzawa et al., 2008) .
The WNT-signalling pathway is known to be involved in a subset of WT (Koesters et al., 1999 (Koesters et al., , 2003 Maiti et al., 2000; Li et al. 2004; Fukuzawa et al., 2004a) . These tumours typically have WT1 mutations and/or CTNNB1 mutations (Koesters et al., 1999; Maiti et al., 2000; Li et al., 2004; Fukuzawa et al., 2004a) . WT1 mutations are strongly associated with ILNR (Beckwith, 1998) that often develop into WTs with ectopic mesenchymal elements (Beckwith et al., 1990; Beckwith, 1998) . A series of immunohistochemical studies of b-catenin in WT have shown that nuclear accumulation of b-catenin is predominantly observed in mesenchymal cells irrespective of CTNNB1 mutations (Koesters et al., 2003; Li et al., 2004; Fukuzawa et al., 2004a Fukuzawa et al., , 2008 Zirn et al., 2006) . These observations suggest a relationship between the mesenchymal lineage in WT and active WNT signalling.
The WTX gene is located in the chromosome band Xq11.1 and encodes a protein of 1135 amino acids. WTX (also called AMER1) has been reported to be deleted or mutated in 7-29% of WTs (Rivera et al., 2007; Perotti et al., 2008; Ruteshouser et al., 2008) . WTX appears to act as an unusual tumour suppressor gene, in which it is inactivated by one-hit mutational events: mutations in the single X chromosome in tumours from males and the active X chromosome in tumours from females cause inactivation of this gene (Rivera et al., 2007; Perotti et al., 2008; Ruteshouser et al., 2008) . Recently, WTX was found to form a complex with AXIN, APC (adenomatous polyposis coli) and b-catenin in the cytoplasm (Grohmann et al., 2007; Major et al., 2007) . WTX was shown to antagonize WNT/b-catenin signalling, as WTX interacted directly with b-catenin to promote its ubiquitination and degradation (Major et al., 2007) . Although two studies have found that mutations in WTX and CTNNB1 were mutually exclusive in WTs (Rivera et al., 2007; Perotti et al., 2008) , one study showed that WTX mutations partially overlapped with CTNNB1 mutations in WTs (Ruteshouser et al., 2008) . However, the majority of the CTNNB1 mutations in tumours with WTX alterations were found in exon 7 or 8, which unlike exon 3 mutations, do not affect the b-catenin serine threonine phosporylation-binding site and therefore may not lead to constitutive b-catenin activation. Mutations in CTNNB1 and WTX were therefore proposed to be not functionally redundant (Ruteshouser et al., 2008) , supporting the notion that b-catenin and WTX act in a common pathway. Alternatively, WTX has been independently reported as an APC-interacting protein controlling the subcellular distribution of APC between the cell membrane and the microtubule of epithelial cells (Grohmann et al., 2007) , suggesting another tumour suppressor function of WTX independent of WNT signalling.
Given the importance of WTX in WNT signalling, we investigated the relationship between tumour lineages in WT and WNT-signalling activation, including the involvement of WTX in the WNT-signalling pathway. The predominance of b-catenin nuclear accumulation in WT mesenchymal cells suggested that aberrant WNTsignalling activation is a consequence of the tumourinitiating lineage, independent of an association with WT1 mutations. We also examined whether WTX mutations are restricted to the WNT-dependent mesenchymal lineage.
Results

CTNNB1 mutations and nuclear accumulation of b-catenin in WTs
We examined 59 tumours for CTNNB1 mutations in exons 3, 7 and 8 (Table 1a) . Thirteen tumours had CTNNB1 mutations, with 10 in exon 3 (T2-4, 7-9, 11, 17-19) and three in exon 7 or 8 (T1, 6, 13). We next examined 53 tumours by immunohistochemistry (IHC) for nuclear accumulation of b-catenin. The intensity and distribution of nuclear staining of b-catenin were variable both within and between tumours as we and other groups have previously reported (Koesters et al., 2003; Fukuzawa et al., 2004a; Li et al., 2004; Fukuzawa et al., 2007) . Nuclear immunostaining of b-catenin was detected predominantly in the undifferentiated mesenchymal cells and sometimes in the blastemal cells in 17 tumours (T2-4, 6-14, 16-20) (Table 1a) .
Wilms tumours with mesenchymal differentiation have active WNT signalling Unsupervised hierarchical clustering analysis classified WTs into two major groups, according to the presence or absence of ectopic mesenchymal elements (myogenesis, chondrogenesis) ( Figure 1a ). The first group (Cluster A) consisted of 15 tumours with ectopic mesenchymal elements, of which 9 contained ILNR. Twelve tumours were analysable by IHC, of which 10 tumours had CTNNB1 mutations and 7 tumours had WT1 mutations (Figure 1a) . Remarkably, all 12 tumours were found to have nuclear accumulation of b-catenin ( Figure 1a) . Significantly, nuclear accumulation of b-catenin and/or CTNNB1 mutations were exclusively observed in this cluster, while neither nuclear accumulation of b-catenin nor CTNNB1 mutations was found in cluster B that had no ectopic mesenchymal elements ( Figure 1a) . Therefore, cluster A was considered to be WNT-dependent.
To examine the relationship between the lineage specificity and activated WNT signalling, we compared expression profiles between the two groups. Molecular features in cluster A characterized the ability to differentiate into multiple mesenchymal lineages. Especially, a sequential myogenic differentiation signature was prominent (Table 2a) . Transcription factors (PAX3, EYA2, MEOX2, LBX1) that are expressed in the paraxial mesoderm and contribute to the specification of myogenesis were present (Ridgeway and Skerjanc, 2001) . Myogenic regulatory transcription factors (MYF5, MYOD1, MYF6, MYOG) and a cofactor (MEF2C), which are subsequently required for myogenesis, were also significantly upregulated. CDH15 is expressed in myoblasts and myotube-forming cells. Transcription factors (TBX3, MSX1, SOX8) and a notch pathway ligand (JAG2) that determine limb patterning originating from the mesoderm were upregulated. Other categories characterizing mesenchymal lineages included genes for transcription factors involved in early mesodermal lineages, chondrogenesis, osteogenesis, hemangiogenesis, adipogenesis and stromagenesis (Table 2a) . Another major pathway involved in cluster A was TGF-b (transforming growth factor-b) signalling (TGFB2, FST, BMP1, BMP2, BMP3), which is known to contribute to mesenchymal phenotypes and chondrogenesis (Wang et al., 2005; Zavadil and Bottinger, 2005) .
The relative overexpression of genes in cluster A tumours, discussed here and shown in Table 2a , indicated divergent mesenchymal differentiation potential, which is similar to that of pluripotent mesenchymal stem cells (MSCs) (Mishra et al., 2005) . Consistent with the histological features of ILNR-derived WTs that often have various ectopic mesenchymal elements, the Figure 6 ) are in the second column from the right. WT1 and CTNNB1 mutations were previously examined in tumours (Fukuzawa et al., 2004a) referred to as reference 1. CTNNB1 mutations have been identified in tumours with IGF2 LOI (Fukuzawa et al., 2008) referred to as reference 2. The whole coding region of CTNNB1 was examined in tumours (Fukuzawa et al., 2007) (Table 2a) . A number of putative stem cell markers were also identified (Table 2a) .
The second major cluster of WTs (cluster B) was distinct from cluster A with molecular features of early kidney epithelial development (WT1, PAX8, ITGA8 and FGFR2), supporting the fact that the origin of tumours was from a kidney epithelial (metanephrogenic) lineage (Table 2b, Supplementary Table S2b) . Cluster B contained no molecular features of active WNT signalling, but instead had genes (CXXC4, NLK) that negatively regulate the canonical WNT-signalling pathway (Table 2b ). In contrast, the expression profiles of cluster A indicated that the WNT-signalling pathway was persistently active and included several WNT target genes (LEF1, PITX2, FGF18, FST, AXIN2, RARG, LGR5, CSPG2, DKK1, GAD1, SIM2, TCF4, FGF9) and WNT antagonists (WIF1, DKK1, SFRP4, SFRP2, NKD2), which function as a feedback mechanism to persistent activation (Li et al., 2004) (Table 2a) . A number of the MSC-like, WNT signature and early nephrogenic genes were confirmed by quantitative realtime PCR (QPCR) (Supplementary Tables S2a and S2b ).
Unsupervised clustering analysis of WTs using WNT target genes
To confirm the role of WNT signalling in the WT mesenchymal lineage, a second unsupervised clustering was carried out using only WNT-related genes ( Figure 1b) . In addition to our data set of WNT target genes (Table 2a) , we compiled all differentially expressed As previously reported by Fukuzawa et al. (2004b) . b As previously reported by Fukuzawa et al. (2007) . c As previously reported by Fukuzawa et al. (2004a) . d As previously reported by Fukuzawa et al. (2008) . e The mutation and the polymorphism have been previously reported by Rivera et al. (2007 Table S3 ). Using the program Cluster (Eisen et al., 1998) , a data set consisting of 29 genes (represented by 75 probe sets, Figure 1b ) and 36 samples were analysed using uncentered average linkage clustering (Pearson's correlation). Many of the WNT target genes on the array were represented by multiple probes, all of which showed reproducible patterns of gene expression (Figure 1b) . Similar to the previous clustering using all genes (Figure 1a ), a mesenchymal cluster (A) and epithelial cluster (B) were again generated using this refined unsupervised clustering analysis. Although clusters A and B shown in Figures 1a and b had minor changes, the main group consisting of 14 WNT-dependent tumours (cluster A in Figure 1a ) remained in the WNT cluster (Figure 1b ), thereby confirming a strong relationship between the mesenchymal lineage and WNT-signalling pathway (Figure 1b ).
Deletions and mutations of WTX in WTs
Fifty-nine WTs were screened for deletions of WTX using multiplex ligation-dependent probe amplification (MLPA) analysis. WTX deletions were detected in 12 tumours, with 9 in female (T5, T13, T14, T23-25, T36, T42, T43) and 3 in male (T7, T21, T22) (Tables 1a and b with examples shown in Figure 2b ). Three tumours (T5, T25, T36) involved a deletion of the Xp marker as well as the Xq markers, indicating the loss of a whole X chromosome (example shown in Figure 2b ). The boundaries of the Xq11.1 deletions in 12 of these WTs with WTX deletions are shown in Figure 2a . WTX deletions were not identified in any matched normal tissues from children with deletion-bearing tumours Figure 1 (a) Unsupervised clustering analysis. An unsupervised clustering analysis performed with a data set consisting of the 520 genes with the most variable expression across all arrays. M, ectopic mesenchymal elements ( þ ); B, nuclear accumulation of b-catenin; W, WT1 mutation; C, CTNNB1 mutation; N, no information available for immunostaining; functional WTX mutations or deletions are highlighted in yellow. Cluster A consists of 15 WTs with ectopic mesenchymal elements, whereas cluster B is composed of 21 WTs that recapitulate kidney epithelial development without ectopic mesenchymal differentiation. As nuclear accumulation of b-catenin and/or CTNNB1 mutations are exclusively observed in cluster A, this cluster is considered to be WNT dependent. (b) Unsupervised clustering analysis using WNT target genes. M, ectopic mesenchymal elements ( þ ); B, nuclear accumulation of b-catenin; W, WT1 mutation; C, CTNNB1 mutation; N, no information available for immunostaining; functional WTX mutations or deletions are highlighted in yellow. Compared with the clustering analysis in Figure 1a , one mesenchymal tumour (T15) moved from cluster A to B, whereas two tumours (T37, T38) moved from cluster B to A. However, the main group consisting of 14 WNT-dependent tumours in cluster A of Figure 1a remained in the WNT cluster.
( Table 1b) . We next examined the entire coding region of the WTX gene of 47 tumours that had no WTX deletions. Five nucleic acid changes were detected from seven patients (six female, one male): two cases (T4, T59) had an identical synonymous single-nucleotide polymorphism, two (T17, 18) had the same missense mutation, two (T6, T16) had nonsense mutations and one (T1) had a frame shift deletion resulting in a truncated protein (Table 1b) .
Functional inactivation of WTX Quantitative real-time PCR for WTX expression was performed using cDNA from 53 WTs. We evaluated inter-gender and inter-histological variability in WTX expression to assess any relationship with the transcriptional inactivation of WTX in female-derived tumours. There were no significant changes between male-and female-derived tumours with or without WTX mutations ( Figure 3a ). There were also no remarkable changes between two histological types with or without WTX mutations (Figure 3b ). WTX was expressed at extremely low levels in seven female-derived tumours with WTX deletions (T5, T13, T14, T23, T24, T42, T43) (Figure 3c ), indicating loss of WTX on the active X chromosome (Xa). However, the levels of WTX expression in two female-derived epithelial tumours with WTX deletions (T25, T36) were close to the average level of WTX expression in female-derived tumours with WTX wild-type ( Figure 3a ) and epithelial lineage tumours with WTX wild-type (Figure 3b ). This suggested that WTX on the inactive X chromosome (Xi) is lost in these tumours, both of which had loss of a whole X chromosome. As XIST is transcribed only from Xi, loss of Xi in T25 and T36 was confirmed by measuring XIST expression using QPCR (Figure 4) . Therefore, events involving WTX do not selectively occur on the Xa, as previously assumed (Perotti et al., 2008) . Two malederived tumours with WTX deletions (T7, T21) had low WTX expression (Figure 3c ), whereas the third tumour (T22) had detectable levels of WTX expression (Figure 3c ). T22 also showed incomplete deletion by MLPA (Figure 2b ), suggesting contamination of the tumour sample with normal kidney tissue or a mosaic deletion.
To examine whether WTX mutant alleles were expressed from the Xa or Xi, sequencing of WT cDNA was also carried out. Sequencing of the corresponding Abbreviation: TGF-b, transforming growth factor-b. Each bar in the graphs shows the ratios of genes compared with the average of three normal female blood samples: ratios of approximately 0.5 and 1.0 indicate single and two copy numbers of genes, respectively. Both a designed probe and an MRC probe also target the same gene (HCA127), indicating the reliability of the designed probe. The probe for Xp11.23 (UBQLN2) confirms genders as well as the other probes on the X chromosome and also provides ranges of deletions of X chromosome in female tumours. Loss of heterozygosity (LOH) analysis for 16q12 confirmed the MLPA data on 16q12 (ORC6L), also providing another indication of a single copy number (T25, this tumour had LOH for both 16p and q). The deleted regions of Xq11.1 in female tumours (T13, T24, T25) show one copy number of genes on the X chromosome. WTX deletions in male tumours show lack of signals from Xq11.1 target genes (T7, T21); a male tumour (T22) shows significant reductions of the ratios of genes spanning from WTX to MTMR8, compared with the other genes, indicating a mosaic deletion of Xq11.1.
WNT signalling and lineage specificity in Wilms tumour R Fukuzawa et al cDNA from three tumours with truncating mutations indicated mutant WTX allele expression in all tumours (T1, T6, T16) (Table 1b) . Sequencing of the corresponding cDNA from tumours with a missense mutation indicated wild-type WTX allele expression in one tumour (T18) ( Figure S1a ). The mutant allele was methylated, suggesting that the unmethylated wild-type allele was expressed (Supplementary Figure S1b) .
Coincident WTX and CTNNB1 alterations in WTs
Six WTs with WTX alterations had CTNNB1 mutations (T1, T6, T7, T13, T17 and T18): CTNNB1 mutations were found in exon 7 or 8 (T1, T6 and T13) and exon 3 (T7, T17 and T18). In those tumours with exon 3 CTNNB1 mutations, two had missense mutations in WTX with expression of the wild-type allele, indicating that the mutant WTX alleles were inactivated by random X-chromosome inactivation (T17, T18) (Table 1b) .
Histologic features and b-catenin IHC in WTs with WTX deletions/mutations
Seven WTX-mutant tumours had ectopic mesenchymal elements (T1, T5-7, T13, T14, T16), whereas six WTX-mutant tumours lacked ectopic mesenchymal elements (T21-24, T42, T43) (Table 1a) . Of the WTX-mutant tumours with ectopic mesenchymal elements, five were analysable by IHC and had positive nuclear staining for b-catenin (T6, T7, T13, T14, T16, with an example shown in Figure 5a ), as well as being located in a cluster featuring high expression of WNT target genes (Figure 1b) . Of the six WTX-mutant tumours that were negative for nuclear and b-catenin staining, four (T21-24, an example shown in Figure 5b ) were available for T5  T13  T14  T23  T24  T25  T36  T42  T43  T7  T21 microarray analysis and were all grouped into a separate cluster featuring under-expression of WNT targets (Figure 1b) .
Analysis of WNT signatures in WTs with WTX alterations
We wished to determine whether WTX mutations upregulate WNT target genes in WTs. Fifty-three tumours including all 13 WTX-mutant tumours were classified into four genotypes according to the presence or absence of WTX and CTNNB1 mutations and the histological types (Table 1a; Figure 6 ) for QPCR assay. WTX-mutant tumours from the mesenchymal lineage had upregulated WNT-related genes, whereas those from epithelial lineage did not, suggesting another role for WTX mutations in the epithelial tumour lineage. Regardless of the genotypes, the tumours arising from the epithelial lineage did not show aberrant WNT-signalling activation, whereas almost all tumours with of mesenchymal origin showed upregulation of WNTrelated genes, again confirming the relationship between the mesenchymal lineage and aberrant WNT signalling.
Association of WTX mutations with 11p15.5 loss of heterozygosity (LOH) and IGF2 loss of imprinting (LOI) In the 13 tumours with functional WTX mutations, four had IGF2 LOI, three had normal IGF2 imprinting and six had 11p15 LOH, of which two had WT1 mutations, indicating no significant relationship between WTX and alterations at 11p15 (Table 1b) .
Discussion
Gene expression profiling confirmed that WTs arise from two different maturational lineages. Our findings suggested that WTs with the mesenchymal lineage originate from specific precursor cells, followed secondarily by activation of the WNT-signalling pathway (Figure 7 ). This conclusion is based on identification of expressed WNT-related genes restricted to WTs of the mesenchymal lineage. The present models of WT molecular genetics focus on the relationship between WT1 mutations and activation of the WNT-signalling pathway (Koesters et al., 1999; Maiti et al., 2000; Fukuzawa et al., 2004a; Li et al., 2004) . However, we have shown that WNT-signalling activation is seen in a broader spectrum of WTs that have mesenchymal features (Table 1a ; Figure 1b ). This confirmed our earlier observation that WTs of the mesenchymal lineage (arising from ILNR) have CTNNB1 mutations, irrespective of the presence or absence of WT1 mutations (Fukuzawa et al., 2008) .
The expression of many genes was consistent with differentiation along multiple mesenchymal lineages, suggesting that WNT-dependent WTs are derived from an MSC (Figure 7) . In support of this contention, the MSC protein DSC 534 (PRR16), a surface marker found on undifferentiated MSCs (Barberi et al., 2005) , was transcriptionally upregulated. The WNT target gene signature also included several additional stem cell markers.
LGR5 has recently been identified as a key stem cell marker in the intestinal crypt (Barker et al., 2007) . The hepatocyte growth factor receptor (MET) is a putative stem cell marker for rhabdomyosarcoma (Boccaccio and Comoglio, 2006) , which can exert positive feedback on b-catenin activity through a pathway that involves the BCL9L-mediated enhancement of b-catenin transcription (Table 2a) . ABCG2 and ABCB6, ATP-binding cassette (ABC) transporter multidrug resistance subfamily members, were also differentially expressed in the WNT-dependent tumours. ABC transporters have been identified as markers of a variety of adult tissue stem cells as well as cancer stem cells (Bunting, 2002) . In addition to stem cell surface markers, active WNT signalling provides a putative mechanism for self-renewal in WTs with ectopic mesenchymal differentiation. Differential expression of TCF4, a key mediator of canonical WNT signalling through b-catenin, provides additional evidence for this mechanism, as TCF4 is required for the self-renewal of normal intestinal stem cell (Pardal et al., 2003) .
Significantly, even if b-catenin was mutated in WT of mesenchymal origin, it was not always present in the nucleus of all WT histological components. b-catenin is normally localized within the cytoplasm or the cell membrane in the epithelial component of WT (Koesters et al., 2003; Li et al., 2004; Fukuzawa et al., 2004a) . The absence of canonical WNT signalling in the epithelial elements despite the presence of b-catenin mutations suggests a different role for b-catenin in the genesis of the epithelial component of WT. That activated b-catenin is not located in the nucleus of WT epithelial components but rather the cytoplasmic membrane suggests b-catenin may have a role in disrupting the adherens junction leading to incomplete epithelial differentiation. (Table 1a ). The mesenchymal lineage across all four types correlated with activated WNT signalling, as tumours with mesenchymal differentiation generally had higher mean expression of WNT target genes than the epithelial tumours in Type III and IV. The mean expression levels of c-MYC, MET and LGR5 in Type III with mesenchymal histology are similar or higher than those of Type I and II, suggesting the involvement of WTX in the WNT pathway in Type III with the mesenchymal lineage. Meanwhile, the range of expression levels of those genes in Type IV with mesenchymal histology are not constant, as one tumour (T15) exceptionally did not follow the WNT signature (see Figure 1b legend ).
The question arises as to the role of b-catenin mutations in WTs, given that canonical WNT signalling is seen only in the mesenchymal component. The most plausible explanation is that CTNNB1 mutations play a role in MSC self-renewal (Beachy et al., 2004) , leading to differentiation into the respective WT mesenchymal components. WNT signalling has been shown to be required for MSC self-renewal and lineage-specific differentiation (Etheridge et al., 2004; Lindsley et al., 2006) . Persistent WNT-signalling activation causes hyper-self-renewal of stem cells and the initiation and growth of many types of cancers (Beachy et al., 2004) . In the medulla of the developing kidney, only the mesenchymal cell show transient nuclear b-catenin staining (Eberhart and Argani, 2001; Fukuzawa et al., 2004a) , suggesting that canonical WNT signalling is required for stem cell self-renewal. ILNR, precursor lesions also often arise from the same region corresponding to the stromagenic phase of the developing kidney (Breslow et al., 2006) . ILNR most likely contain MSCs, because they generate not only mesenchymal tumour elements, but also epithelial structure (Beckwith et al., 1990) (Figure 7) . In WT, WNT-dependent stem cells should also persist within the b-catenin nuclear positive mesenchymal component of the tumour.
We identified an unusual association between CTNNB1 mutations and WTX alterations in agreement with previous study (Ruteshouser et al., 2008) . All three tumours with CTNNB1 mutations in exon 7 or 8 had WTX alterations, whereas only 1 of 10 tumours with exon 3 CTNNB1 mutations had a functional WTX deletion. Thus, the frequency of co-clustering of WTX with exon 3 CTNNB1 mutations was significantly lower than with exon 7 or 8 mutations (Li et al., 2004) , although CTNNB1 mutations in exon 3 are more commonly seen in WTs (Koesters et al., 1999; Maiti et al., 2000; Li et al., 2004) . Most likely, mutations in exon 7 or 8 can activate b-catenin, but the mutant activity may be not sufficient for WNT target activation compared with mutations in exon 3. Previous cotransfection assays of b-catenin have shown that mutations in exon 7 or 8 (K335I, W383R) generated increased activity by only up to half of exon 3 mutations (del S45) (Li et al., 2004) . Compared with mutations in exon 3, CTNNB1 mutations in exons 7 and 8 might therefore not be sufficient to stabilize b-catenin, and require the loss of WTX function as well.
WTX is proposed to be involved in the canonical WNT-signalling pathway. We therefore evaluated the relationship between WTX and the canonical WNTsignalling pathway in WT. Surprisingly, tumours with WTX mutations were almost equally divided between the mesenchymal-and epithelial-derived tumours; the latter did not involve activated canonical WNT signalling. We suggest that WTX has multiple functions depending on the initiating WT lineage, with WTX functioning with the canonical WNT pathway only in tumours arising from the mesenchymal lineage. This suggestion is based on several observations in tumours with mesenchymal differentiation. These include nuclear accumulation of b-catenin, an unusual co-clustering of CTNNB1 non-hot spot mutations with WTX mutations, and upregulation of the WNT target genes.
An explanation for the role of WTX mutations in the epithelial lineage tumours might come from WTX-APC interaction. WTX binds APC and controls the change in localization of APC from microtubules to the plasma membrane of epithelial cells (Grohmann et al., 2007) . APC has several functions related to tumour suppressor activities including cytoskeleton organization, chromosomal segregation, cell adhesion and motility (Fodde, 2003) . As an APC-binding protein, multiple functions of the WTX tumour suppressor activity would be expected. Loss of WTX may consequently contribute to WTs arising from the epithelial lineage by affecting functions that are APC dependent. Abrogation of WTX function may therefore not exclusively affect the WNT-signalling pathway in WT, with different functions of WTX being determined by the tumour-initiating cell lineage.
Materials and methods
WT samples
Fifty-nine tumours (18 male, 41 female) were examined for deletions and mutations of CTNNB1 and WTX, of which 57 tumours were available for histological examination. None of the patients had a family history of WT. Two patients (T13 and T25) had associated non-syndromic over-growth syndrome (Morison et al., 1996; Fukuzawa et al., 2008) and one patient (T7) had associated hemihyperplasia (Fukuzawa et al., 2008 
Microarray analysis
Thirty-six of 59 WTs were available for micoroarray analysis. We previously performed a microarray analysis on a different platform (Oligo cDNA microarray) for 14 tumours (Fukuzawa et al., 2008) , of which 13 were used in this investigation. Total RNA was isolated from frozen samples using Tri Reagent (Molecular Research Center, Cincinnati, OH, USA) and RNeasy purification columns (Qiagen, Hilden, Germany). RNA was quantitated using the BioRad Experion Automated Electrophoresis System (BioRad, Hercules, CA, USA). Doublestranded cDNA was synthesized from 5 mg of total RNA, and biotin-labeled cRNA was produced from cDNA using the Affymetrix In Vitro Transcription kit with Megascript components according to Affymetrix protocols (Affymetrix, Santa Clara, CA, USA, http://www.affymetrix.com). Twenty mg of biotinylated cRNA was used for fragmentation, and 15 mg of fragmented cRNA was hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays. Washing and staining was performed on an Affymetrix Gene Chip Fluidics Station 450 using scripts recommended by the manufacturer, and chips were scanned with an Affymetrix 7G Plus scanner. Chips were normalized and expression levels were calculated using Robust Multichip Analysis (RMA) (Irizarry et al., 2003) in BRBArraytools software (http://linus.nci.nih.gov).
Unsupervised clustering analysis
Hierarchical clustering of WTs was performed using the program Cluster (Eisen et al., 1998) . A data set consisting of the 520 genes with the most variable expression across all arrays and 36 samples was analysed using uncentered average linkage clustering (Pearson correlation), and the results were visualized using the program Treeview (Eisen et al., 1998) . After classifying the 36 tumours into two major clusters based on the unsupervised hierarchical clustering analysis, differential gene expression was determined using the R package Limma (Smyth, 2004) . Limma computes a moderated tstatistic (t* ¼ M/SE*) for each gene in a comparison. M is the log2 fold change and SE* is an estimate of the standard error calculated using data from all arrays by empirical Bayes methods. A moderated P-value is obtained from t* following adjustment for multiple testing using Benjamini and Hochberg's method to control the false discovery rate. Genes with a P-value greater than 0.05 were selected as significantly different, giving a false discovery rate of less than 5%.
Identification of mesoderm differentiation and nephrogenic signatures As WT recapitulates kidney development, we linked the molecular signatures in WT to normal embryogenesis (mesoderm differentiation) and nephrogenesis by searching a kidney development database (http://golgi.ana.ed.ac.uk/kidhome. html), embryology databases (http://embryology.med.unsw. edu.au/Notes/urogen.htm), the SOURCE (http://smd.stanford. edu/cgi-bin/source/sourceSearch) and GATHER (http://gather. genome.duke.edu/).
Validation of MSC-like and WNT signatures
To validate the differential expressed genes on between the two clusters, QPCR assays were performed on an ABI PRISM 7900HT Sequence Detection System using ABI TaqMan probes as previously described (Fukuzawa et al., 2008) . TaqMan probe numbers and results are shown in Supplementary Tables S2a and S2b .
MLPA analysis
We screened 59 WTs for WTX deletions using MLPA analysis (Schouten et al., 2002) with the SALSA MLPA Kit P181 (MRC Holland, Amsterdam, The Netherlands). The probe set contained 47 different probes (MRC probes) for the centromeric regions of the whole chromosomes. We designed a further seven synthetic probes that targeted sequences in ARHGEF9, WTX, ASB12, MTMR8 and HCA127 (KIAA1166) within the Xq11.1 to Xq11.2 region (Figure 2a) , avoiding single-nucleotide polymorphisms and producing fragments of a unique size. The information for designed probes and the detailed method are available in the Supplementary information Table S1 (see also Jenkins et al., in press ).
Mutational analysis for WTX Tumours without deletions were screened for mutations as previously reported (Rivera et al., 2007) . If mutations were observed in the tumour DNA samples, the matched normal tissues and/or tumour cDNA samples were also sequenced. Sequencing of PCR products was performed using ABI BigDye Terminator v3.1 Cycle Sequencing kit and an ABI3730 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. Mutations were detected using Sequencher software (Gene Codes Corporation, Ann Arbor, MI, USA).
Relative expression of WTX, XIST and WNT direct and indirect genes Fifty-three tumours were available for QPCR. Relative expression levels were measured using ABI TaqMan probes: FAM123B (WTX, Hs.00403552), XIST (Hs.01077162), LGR5 (Hs.00173664), WIF1 (Hs.00183662), DKK1 (Hs.00183740), MET (Hs.00179845), c-MYC (Hs.00153408) and Absolute QPCR ROX mix. The expression levels of these genes in each tumour sample were normalized to an endogenous control gene UBE2G2 (Hs.00163326) as previously described (Fukuzawa et al., 2008) .
WT1, CTNNB1 mutations, IGF2 imprinting and 11p LOH analysis
We examined 59 WTs for WT1 mutations, 11p13 LOH, 11p15 LOH, imprinting status of IGF2 and CTNNB1 mutations (exons 3, 7 and 8) as previously described (Ogawa et al., 1993; Fukuzawa et al., 2004a Fukuzawa et al., , 2004b Fukuzawa et al., , 2008 . Previously published cases are listed in Table 2a .
Immunohistochemistry
Immunohistochemistry was carried out for b-catenin using one block per case from 53 tumours as previously described (Fukuzawa et al., 2007) .
